IJPSR (2011), Vol. 2, Issue 9



INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH (Research Article)



Received on 11 May, 2011; received in revised form 26 June, 2011; accepted 14 August, 2011

ANTI-INFLAMMATORY ACTIVITY OF NOVEL SUBSTITUTED QUINOXALINE HETEROCYCLES

Smd. Noorulla* and N. Sreenivasulu

MESCO College of Pharmacy¹, Karwan Road, Mustaidpura, Hyderabad, Andhra Pradesh, India VL College of Pharmacy², Raichur, Karnataka, India

Keywords:

Quinoxaline, Isoniazid, Anti- inflammatory activity, Synthesis

Correspondence to Author:


Smd. Noorulla

Assistant Professor, MESCO College of Pharmacy, Karwan Road, Mustaidpura, Hyderabad, Andhra Pradesh, India

ABSTRACT


Substituted Quinoxaline have received considerable attention during last two decades as they are endowed with variety of biological activities and have wide range of therapeutic properties. A literature survey indicates that quinoxaline derivatives possess different pharmacological and biological activities, of which the most potent is anti-inflammatory activity. In view of above literature survey, we thought to synthesize a novel substituted quinoxaline system.

INTRODUCTION: Quinoxaline is the subject of considerable interest from both academic and industrial Perceptive. Among the various classes of the nitrogen containing heterocyclic compounds Quinoxaline are important component of severally pharmacologically active compounds. Although rarely described in nature synthetic quinoxaline ring is a part of number of antibiotics which are known to inhibit the growth of Gram Positive bacteria and are also active against various transplantable tumors. Quinoxaline is commonly called as 1, 4-diazanaphthalene or benzopyrine. The approved numbering of the ring atom is shown below.




Quinoxaline and its derivatives are mostly of synthetic origin. Some quinoxaline derivatives are known to posse's antibacterial activities. The quinoxaline antibiotics are agents of bicyclic desipeptide antibiotic that have been reported activity against gram-positive bacteria and certain tumors and to inhibit RNA synthesis ¹. Quinoxaline has also been used in reactive dyes and pigments, azo dyes, fluroscein dyes and it also forms a part of certain antibiotics.

Quinoxaline is a low m.p. $29-30^{\circ}$ C and is miscible with water. It is weakly basic (*p*ka 0.56) and thus considerably weaker base than the isomeric diazonapthalenes namely cinnoline (*p*ka 2.42), pthalizine (*p*ka 3.47) or quinazoline (*p*ka 1.95). 2-Hydroxy but not 2-amino quinoxaline exist in tautomeric forms.



The fusion of one or two benzene rings in quinoxaline and phenazine increases the number of resonance structure, which are available to these systems. It possesses the dipole moment of zero. Quinoxaline itself is prepared by the reaction of *o*-phenyldiamine and glyxol ². Simillarly2- Methyl Quinoxaline has been prepared by the reaction of *o*-phenyldiamine and pyruvaldehyde.




Taylor ³ recently reported that 1-(p-tolysulfonyl)-2- phenyloxirane, obtained from the condensation of chloromethyl *p*-tolysulfone with benzaldehyde, on


reaction with *o*-Phenylenediamine yields 2-phenyl quinoxaline in good yield.

$$NH_{2} + C_{6}H_{5}CH - CHSO_{2}-Tol-p \xrightarrow{DMF} N + C_{6}H_{5}$$


A number of simple variations of the dialdehyde diamine reaction appear to work well. Thus replacement of the dialdehyde with α -halogenketone result in the formation of 2-substituted quinoxaline.2-phenylquinoxaline has been prepared in this manner from phenacyl chloride and *o*-phenylenediamine ⁴.



Compounds containing 1, 2, 3-tricarbonyl functionality have been used in the synthesis of a variety of Heterocyclic derivatives ⁵. The tricarbonyl group containing compounds can be prepared by treating 3keto ester with *p*-nitro sulphonyl peroxide ⁶, to give 2-(*p*- nitro phenyl)-sulfonyl) oxy)-3-keto esters.




Treatment of the resulting 2-(nosyloxy)-3-ketoesters with triethyl amine (TEA) in benzene at room temperature results in *vic* tricarbonyl compound. The tricarbonyl compound can be trapped *in situ* with *o*-phenylenediamine to give quinoxaline derivatives. Quinoxaline forms salt with acids. Nitration occurs only under forcing conditions (Conc.HNO₃, Oleum) to give 5-nitroquinoxaline (1.5%) and 5, -7 dinitroquinoxaline (95%).



2-chloroquinoxaline has been prepared by the action of phosphorous oxychloride on quinoxaline -2-one or quinoxaline-1- oxide 7 .

Oxidation of quinoxaline results in the formation of the product depending upon the nature of the oxidizing agent employed. With alkaline potassium permagnate pyrazine 2, 3-dicarboxylic acid is formed, while with peracid quinoxaline *di*-N-oxide results. 2-methylquinoxalineon selenium dioxide oxidation affords quinoxaline 2- carboxaldehyde.



Alkyl radicals produced from acyl peroxide or alkyl hydro peroxide give high yields of 2-substituted alkyl derivatives. Reduction (Na, C_2H_5OH) of quinoxaline gives a 1, 2, 3, 4-tetrahydro derivatives.

Objectives: Most of the present diseases are due to the invasion by the pathogenic organisms like bacteria, fungal, virus, ricketsia. To treat these diseases many potent and broad spectrum antibiotics were discovered eg: Ampicillin, Amoxicillin, Carbenicillin, Ofloxacin, Tetracyclines, and Ciprofloxacin etc. Even though antibiotics are life saving drugs in therapeutics but they are potentially harmful. These effects include allergic and anaphylactic reaction, superinfection, development of resistance, destruction of normal nonpathogenic bacterial flora and selective toxicity like aplastic anemia, kidney damage etc.

A considerable amount of research activity is directed towards a potent, more specific and less toxic antibiotics. Substituted quinoxaline have received considerable attention during last two decades as they are endowed with variety of biological activities and have wide range of therapeutic properties. A literature survey indicates that a quinoxaline derivative possesses different pharmacological and biological activities, which of most potent activity is antimicrobial, anti-fungal, anti-inflammatory and analgesic activity. We thought to synthesize novel substituted quinoxaline moiety.

Quinoxaline derivatives are widely distributed in nature and they have been shown to have very interesting biological activities like, anti-bacterial, antifungal, anti-inflammatory and analgesic activity. Hence in present study we plan to synthesize novel substituted quinoxaline derivatives.

Isoniazid is an antitubercular agent used for the treatment of tuberculosis. It is a first line drug and is used along with the rifampicin and ethambutol.

By considering the above facts here with we have planned to synthesize substituted quinoxaline derivatives by incorporating the isoniazid moiety into the quinoxaline moiety and evaluate them for biological activities like anti-bacterial potency and antiinflammatory activity.

Methodology:

Preparation of -2, 3-dihydroxy Quinoxaline (Ia): In to a clean dry round bottom flask introduced o-phenylene diamine (10.7 gms, 0.1 mole) and diethyl oxalate (14.6 ml, 0.1 mole) and the contents were refluxed for 1hr. Cooled and the separated solid was collected by filtration, washed with 25 ml ether and dried. The obtained 2, 3-dihydroxy quinoxaline was recrystallized from DMF, the yield was 90% and the melting point was 360°C (Ia).

Preparation of -2, 3- dichloro Quinoxaline (IIa): In a clean dry round bottom flask introduced 2, 3-dihydroxy quinoxaline (1.67 gms, 0.01 mole), phosphorous oxy chloride (6.25 ml, 0.01mole) and DMF (1ml). The contents of the flask were refluxed for 90 min. The resulting solution was cooled for 4-5 hr, and then the cold solution was poured into crushed ice with gentle stirring with the glass rod. The solid thus separated was collected by filtration, washed with 25 ml of water and dried.

The obtained 2, 3-dichloro quinoxaline was recrystallized from solution of chloroform and n-hexane (1:1), the yield was 85% and the melting point was 152°C (IIa).

Preparation of 3-chloro-2-hydrazino quinoxaline (IIIa): In a clean dry round bottom flask introduced 2, 3dichloro quinoxaline (1.60 gms, 0.01mole), hydrazine hydrate (1ml 0.01mole), methanol (25ml) and all the contents of the flask were refluxed for 20 min at refluxing temperature. Cooled and separated solid was collected by filtration, washed with 25 ml water and dried. The obtained 3-chloro-2-hydrazino quinoxaline was recrystallized from methanol, the yield was 75% and the melting point was 182°C. **(IIIa)**

Preparation of 3-chloro-2-(p-methoxybenzylidene hydrazinyl)-quinoxaline(IVa₁): In to a clean dry round bottom flask introduced 3-chloro-2-hydrazino quinoxaline (IIIa) (1.95 gms, 0.01 mole), 4-methoxybenzaldehyde (1.20 ml, 0.01 mole) and glacial acetic acid (15 ml) and the contents were refluxed for 2 hr. Cooled and the solution was poured into ice cold water with continuous stirring. The solid thus separated was collected by filtration and washed with

25 ml water and dried. The obtained 3-chloro-2-(pmethoxybenzylidene hydrazinyl)-quinoxaline was recrystallized by using ethanol (90%), the yield was 71% and the melting point was 130-132 °C (IVa₁). The other Schiff's bases were prepared by using same procedure as above (IVa₂-IVa₁₀). The physical characterization data was given in the Table-I

Preparation of N-(3-(isoniazidyl)-N'-(2-(2'-(p-methoxy benzylidene hydrazinyl))-quinoxaline (Va₁) :


Procedure: In a clean dry round bottom flask introduced 3- chloro- 2- (p- methoxybenzylidene hydrazinyl) - quinoxaline (**IVa**₁) (3.12 gms, 0.01 mole),

isoniazide (1.37 gms, 0.01 mole) and pyridine (25ml). The above contents of the RB flask were refluxed for 24 hr. Cooled and the solution was poured into ice cold water with continuous stirring. Then the solid thus separated was collected by filtration and washed with 25 ml water and dried. The obtained N-(3-(isoniazidyl)-N'-(2-(2'-(p-methoxy benzylidene hydrazinyl))- quinoxaline was recrystallized by using aqueous DMF, the yield was 60% and the melting point was 140-142°C (Va₁). The other compounds of the series were prepared by using same ocedure as above (Va₂-Va₁₀). The physical characterization data was given in the Table-II

TABLE 1: CHARACTERIZATION DATA OF SYNTHESIZED COMPOUNDS (IVA1-IVA10)

N NHN=CH-R CI								
S. No	Compound code	R	Melting point	Molecular Formula	Molecular Weight	%Yield		
1	IVa ₁	OMe	130-132 °C	C ₁₆ H ₁₃ N ₄ OCI	312	71		
2	IVa ₂		176-178 °C	$C_{15H_{10}N_5O_2CI}$	327	63		
3	IVa ₃	ОН	104-106 °C	$C_{15}H_{11}N_4OCI$	298	59		
4	IVa ₄	— ОН	232-236 °C	$C_{15}H_{11}N_4OCI$	298	68		
5	IVa ₅		134-138 °C	$C_{19H_{13}N_4Cl}$	332	58		
6	IVa ₆	0Me	200-204 °C	$C_{16}H_{13}N_4OCI$	312	64		
7	IVa ₇		124-126 °C	$C_{15}H_{10}N_4Cl_2$	317	60		
8	IVa ₈	OMe OMe OMe	220-222 °C	$C_{18}H_{17}N_4O_3CI$	372	60		
9	IVa ₉	cl cl	188-192 °C	$C_{15}H_9N_4Cl_3$	351	55		
10	IVa ₁₀		160-162 °C	$C_{15}H_{10}N_4Cl_2$	317	52		

TABLE 2: PHYSICAL DATA OF QUINOXALINE DERIVATIVES (VA1-VA10)



S.No.	Compound Code	R	Mol. Formula	Molecular Wt.	Melting Point (° C)	Yield %
1	Va ₁	OMe	$C_{22}H_{19}N_7O_2$	413	140-142	60
2	Va ₂		$C_{21}H_{16}N_8O_3$	428	144-146	45
3	Va ₃	-	$C_{21}H_{17}N_7O_2$	399	124-126	53
4	Va ₄	— ОН	$C_{21}H_{17}N_7O_2$	399	178-182	55
5	Va ₅		C ₂₅ H ₁₉ N ₇ O	433	164-166	58
6	Va ₆		$C_{22}H_{19}N_7O_2$	413	156-158	48
7	Va ₇		$C_{21}H_{16}N_7OCI$	417	136-138	62
8	Va ₈		$C_{24}H_{23}N_7O_4$	473	184-186	50
9	Va ₉		$C_{21H_{15}N_7OCl_2}$	452	148-150	65
10	Va ₁₀		$C_{21}H_{16}N_7OCI$	417	158-160	52

Pharmacological Activity:

Anti- inflammatory activity: Inflammation is a normal protective response to tissue injury caused by physical trauma, noxious chemicals or microbiological agents. Inflammation is body response for tissue repair. Inflammation is triggered by the release of chemical mediators vary with the types of inflammatory process and include amines such as histamine, serotonin and lipids such as prostaglandins and small peptides such as kinins. The acute inflammatory response has 3 main functions.

- 1. A transient material called the acute inflammatory exudates occupies the affected area. The exudates carry proteins, fluid and cells from local blood vessels in to the damaged area to mediate local proteins.
- 2. If an infective causative agent (e.g. bacteria) is present in the damaged area it can be destroyed and eliminated by components of the exudates.
- 3. The damaged tissue can be broken down and partially liquefied and the debris removed from the site of damage.

Group	Treatment	Dose mg/kg	Paw oedema volume							
			After 1st hr		After 2nd hr		After 3rd hr		After 4th hr	
			Mean	% ROV	Mean	% ROV	Mean	% ROV	Mean	% ROV
1	Control	0.5ml	0.70	-	0.81	-	0.9	-	1.21	-
2	Standard Diclofenac Sod.	20	0.48	31.4	0.44	45.6	0.50	44.4	0.36	70.2
3	Va ₁	200	0.54	22.8	0.53	34.5	0.57	36.6	0.45	62.8
4	Va ₂	200	0.56	20.0	0.67	17.2	0.62	31.1	0.50	58.6
5	Va ₃	200	0.62	11.4	0.58	28.3	0.6	33.3	0.47	61.1
6	Va ₄	200	0.61	12.8	0.57	29.6	0.57	36.6	0.50	58.6
7	Va ₅	200	0.61	12.8	0.63	22.2	0.62	31.1	0.52	57
8	Va ₆	200	0.55	21.4	0.53	34.5	0.53	41.1	0.43	64.4
9	Va ₇	200	0.55	21.4	0.55	32	0.56	37.7	0.46	61.9
10	Va ₈	200	0.52	25.7	0.49	39.5	0.53	41.1	0.4	66.9

TABLE 3: DATA SHOWING ANTI-INFLAMMATORY ACTIVITY OF QUINOXALINE DERIVATIVES (VA1-VA9)

ROV-Reduction in paw oedema volume

Vag

RESULTS AND DISCUSSION

11

Anti-inflammatory activity: From anti-inflammatory activity studies it was found that compounds showed significant activity. Perhaps the presence of OCH₃ on phenyl nucleus attached to second position of the quinoxaline nucleus may be responsible for marked anti-inflammatory activity.

200

0.57

18.5

From Anti-inflammatory activity evaluation, it was found that compounds showed significant activity. Perhaps the presence of OCH_3 on aromatic system present in 2^{nd} position of quinoxaline nucleus, which may be responsible for marked anti-inflammatory activity.

The above results establish the fact that substituted quinoxaline can be studied further to search for new anti-inflammatory compounds. **CONCLUSION:** From the anti-inflammatory activity evaluation it is very clear that the tested compounds showed near to equipotent activity to that of standard diclofenac sodium employed for the study. From anti-inflammatory activity evaluations, it was found that compounds showed significant activity. Perhaps the presence of OCH₃ group at aromatic system and presence of heterocyclic nucleus may be responsible for marked anti-inflammatory activity.

32.2

0.49

59.5

REFERENCES

0.59

27.1

0.61

- 1. Otsuka H and Shoji J. Tetrahedron 1967; 23: 1536.
- 2. Jones RG and McLaughlin KC. Org Synth 1950; 30: 86.
- 3. Schannk K, Lick C. Synthesis 1983; 392.
- 4. Cheeseman GWH. Adv Het Chem 1963; 2:203.
- 5. Hoffman RV, Kim HO and Wilson AL. J Org Chem 1990; 55: 2820.
- 6. Ahmad Y, Habib MS and Bakhtiari. J Org Chem 1966; 31: 2163.
- Heesoon Lee, Sungmoon Cho, Kwon Namgoong, Jae-Kyung Jung, Jungsook Cho and Sung-II Yang. Bio Org & Med Chem Lett 2004; 14: 1235.
